Alnylam Receives Allowance for Broad New European Patent Covering RNAi Therapeutics
New "Kreutzer-Limmer II'' Patent Covers RNAi Therapeutics towards over 125 Disease Targets
12-Aug-2005 -
Alnylam Pharmaceuticals, Inc. announced the allowance of broad claims from the European Patent Office for a new patent (EP Patent No. 1352061) covering small interfering RNAs (siRNAs), the molecules that mediate RNA interference (RNAi). The new "Kreutzer-Limmer II" patent, which Alnylam acquired ...
adhesion
Alnylam
angiogenesis
+6